Windlas Biotech Ltd (WINDLAS) Q4FY25 Concall Summary - Mar-2025 Qtr
Performance Overview
- Windlas Biotech reported strong revenue growth of 20% Y-o-Y for FY25 and 18% Y-o-Y for Q4 FY25.
- The growth was driven by new customer additions, a broader product portfolio in the Generic Formulations CDMO vertical, and wider market penetration in the Trade Generics and Institutional vertical.
- The company achieved its highest ever earnings per share (INR 29.19) post-listing.
- Windlas Biotech began utilizing Plant 2 extension in Q4 FY25 and received approvals for its injectable facility from several large customers.
- The company paid a dividend of INR 5.5 per share for FY24 and proposed a dividend of INR 5.8 per share for FY25.
Financial Metrics
Log in to Stocksigma to read the Financial Metrics section of this summary.
Operating Performance / Business Segments
Log in to Stocksigma to read the Operating Performance / Business Segments section of this summary.
Key Discussions & Insights
Log in to Stocksigma to read the Key Discussions & Insights section of this summary.
Outlook and Guidance
Log in to Stocksigma to read the Outlook and Guidance section of this summary.
Challenges / Concerns
Log in to Stocksigma to read the Challenges / Concerns section of this summary.
Industry / Competitive Landscape
Log in to Stocksigma to read the Industry / Competitive Landscape section of this summary.
Overall Summary
Log in to Stocksigma to read the Overall Summary section of this summary.